Skip to main content

Advertisement

SpringerLink
Log in

Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer

  • Educational Series / Green Series
  • Molecular Targets in Oncology
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

During the last decade, the development of new drugs known as targeted therapies was the result of a better understanding of the processes involved in the transformation of normal cells into cancer. The term targeted therapy refers to drugs that selectively target specific molecular pathways involved in tumorigenesis or tumour progression. Angiogenesis is important for tumour growth and metastasis, and is an important target for new biological agents. Bevacizumab is a humanised recombinant antibody that prevents vascular endothelial growth factor (VEGF) receptor binding, and inhibits angiogenesis and tumour growth. On February 26, 2004, the Food and Drug Administration approved bevacizumab as first-line treatment for patients with metastatic colorectal cancer (CRC). The integration of targeted therapies in the treatment of colon cancer has resulted in significant improvements in efficacy outcomes. The efficacy of bevacizumab in the treatment of metastatic CRC is presented in this review article.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ries LAG, Melbert D (2008) SEER Cancer Statistics Review, 1975–2005, National Cancer Institute. SEER, Bethesda, MD. http://seer.cancer.gov/csr/1975_2005/, based on November 2007 SEER data submission, posted to the SEER website

  2. Cancer.net. Colorectal cancer: overview. Available at http://www.cancer.net/patient/Cancer+Types/Colorectal+Cancer

  3. Fidler IJ, Ellis LM (1994) The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79:185–188

    Article  PubMed  CAS  Google Scholar 

  4. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186

    Article  PubMed  CAS  Google Scholar 

  5. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676

    Article  PubMed  CAS  Google Scholar 

  6. Dvorak HF (2006) Discovery of vascular permeability factor (VPF). Exp Cell Res 312:522–526

    Article  PubMed  CAS  Google Scholar 

  7. Nagy JA, Vasile E, Feng D et al (2002) VEGF-A induces angiogenesis, arteriogenesis, lymphangiogenesis, and vascular malformations. Cold Spring Harb Symp Quant Biol 67:227–237

    Article  PubMed  CAS  Google Scholar 

  8. Tanaka K, Yamaguchi S, Sawano A, Shibuya M (1997) Characterization of the extracellular domain in vascular endothelial growth factor receptor-1 (Flt-1 tyrosine kinase). Jpn J Cancer Res 88:867–876

    Article  PubMed  CAS  Google Scholar 

  9. Wang L, Zeng H, Wang P et al (2003) Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration. J Biol Chem 278:48848–48860

    Article  PubMed  CAS  Google Scholar 

  10. Zafirellis K, Agrogiannis G, Zachaki A et al (2008) Prognostic significance of VEGF expression evaluated by quantitative immunohistochemical analysis in colorectal cancer. J Surg Res 147:99–107

    Article  PubMed  CAS  Google Scholar 

  11. Takebayashi Y, Aklyama S, Yamada K et al (1996) Angiogenesis as an unfavourable prognostic factor in human colorectal carcinoma. Cancer 78:226–231

    Article  PubMed  CAS  Google Scholar 

  12. Melnyk O, Shuman MA, Kim KJ (1996) Vascular endothelial growth factor promotes tumour dissemination by a mechanism distinct from its effect on primary tumour growth. Cancer Res 56:921–924

    PubMed  CAS  Google Scholar 

  13. Kim KJ, Li B, Winer J et al (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841–844

    Article  PubMed  CAS  Google Scholar 

  14. Warren RS, Yuan H, Matli MR et al (1995) Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 95:1789–1797

    Article  PubMed  CAS  Google Scholar 

  15. Klement G, Baruchel S, Rak J et al (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumour regression without overt toxicity. J Clin Invest 105:R15–24

    Article  PubMed  CAS  Google Scholar 

  16. Rubenstein JL, Kim J, Ozawa T et al (2000) Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2:306–314

    Article  PubMed  CAS  Google Scholar 

  17. Calabrese C, Poppleton H, Kocak M et al (2007) A perivascular niche for brain tumor stem cells. Cancer Cell 11:69–82

    Article  PubMed  CAS  Google Scholar 

  18. Margolin K, Gordon MS, Holmgren E et al (2001) Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 19:851–856

    PubMed  CAS  Google Scholar 

  19. Cobleigh MA, Langmuir VK, Sledge GW et al (2003) A phase I/II dose escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30[5 Suppl 16]:117–124

    Article  PubMed  CAS  Google Scholar 

  20. Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427–434

    Article  PubMed  CAS  Google Scholar 

  21. Gordon MS, Margolin K, Talpaz M et al (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843–850

    PubMed  CAS  Google Scholar 

  22. Jain RK (2001) Normalizing tumour vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987–989

    Article  PubMed  CAS  Google Scholar 

  23. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342

    Article  PubMed  CAS  Google Scholar 

  24. Hurwitz HI, Fehrenbacher L, Hainsworth JD et al (2005) Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23:3502–3508

    Article  PubMed  CAS  Google Scholar 

  25. Avastin prescribing information. Available at http://www.gene.com/gene/products/information/pdf/avastin-prescribing.pdf. Accessed 20 July 2006

  26. Fuchs CS, Marshal J, Mitchell E et al (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C study. J Clin Oncol 25:4779–4786

    Article  PubMed  CAS  Google Scholar 

  27. Fuchs CS, Marshall J, Barrueco J (2008) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol 26:689–690

    Article  PubMed  Google Scholar 

  28. Saltz LB, Clarke S, Díaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019

    Article  PubMed  CAS  Google Scholar 

  29. Köhne CH, De Greve J, Hartmann JT et al (2008) Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol 19:920–926

    Article  Google Scholar 

  30. Ziras N, Polyzos A, Kakolyris S (2008) CAPIRI (capecitabine, irinotecan)+bevacizumab vs FOLFIRI (folinic acid, 5 fluorouracil, irinotecan)+bevacizumab for the treatment of patients with metastatic colorectal cancer (mCRC): interim analysis for safety of a randomized phase III trial. J Clin Oncol 26[Suppl 20]:15008

    Google Scholar 

  31. Grothey A, Sugrue M, Hedrick E (2007) Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): results from a large observational study (BRiTE). J Clin Oncol 25[Suppl 18]:4036

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Second Radiation Therapy Department, Saint Savvas Anticancer Institute of Athens, Alexandra’s Avenue 171, 115 22, Athens, Greece

    Georgios V. Koukourakis & Anastasia Sotiropoulou-Lontou

Authors
  1. Georgios V. Koukourakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anastasia Sotiropoulou-Lontou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Georgios V. Koukourakis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koukourakis, G.V., Sotiropoulou-Lontou, A. Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer. Clin Transl Oncol 13, 710–714 (2011). https://doi.org/10.1007/s12094-011-0720-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-011-0720-z

Keywords

Search

Navigation